Enliven Therapeutics (ELVN) Change in Account Payables (2019 - 2026)

Enliven Therapeutics has disclosed Change in Account Payables across 8 years of filings, most recently posting -$519000.0 for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$519000.0, down 335.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $78000.0 (up 106.93% YoY), and the FY2025 annual result was $817000.0, up 0.86% from the prior year.
• Change in Account Payables came in at -$519000.0 for Q1 2026 at Enliven Therapeutics, down from $828000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q1 2024 to a low of -$1.6 million in Q2 2024.
• The 5-year median for Change in Account Payables is $18000.0 (2022), against an average of -$43000.0.
• Across the five-year window, Change in Account Payables jumped 1005.33% in 2022 and tumbled 5438.89% in 2023, its largest moves.
• Enliven Therapeutics' Change in Account Payables stood at $18000.0 in 2022, then sank by 5438.89% to -$961000.0 in 2023, then jumped by 133.61% to $323000.0 in 2024, then jumped by 156.35% to $828000.0 in 2025, then plunged by 162.68% to -$519000.0 in 2026.
• The last three Change in Account Payables figures came in at -$519000.0 (Q1 2026), $828000.0 (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.